Biologics and Small Molecule Inhibitors for Treating Hidradenitis Suppurativa: A Systematic Review and Meta-Analysis.
Chun-Hsien HuangI-Hsin HuangCheng-Chen TaiChing-Chi ChiPublished in: Biomedicines (2022)
Adalimumab and bimekizumab are the only two biologics effective in achieving HiSCR with acceptable safety profile, whereas adalimumab is the only biologic effective in achieving DLQI 0/1.